A Fixed-Sequence, Drug-Drug Interaction Study Between Multiple Oral Doses of Inarigivir Soproxil and a Single Oral Dose of Midazolam in Healthy Subjects

NCT03493698 | Completed Phase 1 Results

• 2 other identifiers: SBP-9200-HBV-2022018-000607-16
• Study Type: interventional
• Target: 17
• Locations: 1 country
• Sites: 1

Brief Summary

This is a single center, open-label, fixed sequence study to investigate the effect of multiple oral dosing of Inarigivir Soproxil and a single oral dose of Midazolam in Healthy Subjects

Conditions

Drug Interaction Potentiation

Outcome Measures

Primary Outcomes (3)

• Effect of Steady-state Oral Inarigivir on the Single Dose Pharmacokinetics (PK) of Oral Midazolam in Healthy Subjects (Cmax)

  Comparison of Cmax for midazolam between Treatments A and D.

  Day 1 Treatment A and Day 19 Treatment D, respectively

• Effect of Steady-state Oral Inarigivir on the Single Dose Pharmacokinetics (PK) of Oral Midazolam in Healthy Subjects (AUC0-t)

  Comparison of AUC0-t for midazolam between Treatments A and D.

  Day 1 Treatment A and Day 19 Treatment D, respectively

• Effect of Steady-state Oral Inarigivir on the Single Dose Pharmacokinetics (PK) of Oral Midazolam in Healthy Subjects (AUC0-inf )

  Comparison of AUC0-inf for midazolam between Treatments A and D.

  Day 1 Treatment A and Day 19 Treatment D, respectively

Secondary Outcomes (3)

• Number of Participants With Clinical Relevant Clinical Laboratory, Vital Signs, 12-lead ECG, or Physical Examination

  Day -1 to Day 20 and Follow-up (5-9 days post-treatment)

• PK of Inarigivir After Single and Multiple Oral Doses in Healthy Subjects (AUC)

  Day 3 and Day 6 to 19

• PK of Inarigivir After Single and Multiple Oral Doses in Healthy Subjects (Cmax)

  Day 3 and Day 6 to 19

Study Arms (3)

Treatment A: Midazolam

EXPERIMENTAL

All subjects will receive a single oral dose of 2 mg Midazolam on Day 1

Drug: Midazolam

Treatment B and C: Inarigivir

EXPERIMENTAL

All subjects will receive a single oral dose of 400 mg Inarigivir on Day 3, Day 6-18

Drug: Inarigivir

Treatment D: Inarigivir with Midazolam

EXPERIMENTAL

All subjects will receive a single oral dose of 400 mg Inarigivir coa administered with a single oral dose of 2 mg Midazolam on Day 19

Drug: Midazolam; Drug: Inarigivir

Interventions

Midazolam DRUG

Midazolam

Treatment A: Midazolam; Treatment D: Inarigivir with Midazolam

Inarigivir DRUG

Inarigivir

Also known as: Inarigivir Soproxil, SB 9200

Treatment B and C: Inarigivir; Treatment D: Inarigivir with Midazolam

Eligibility Criteria

• Age: 18 Years - 55 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Gender : male or female
• Age : 18-55 years, inclusive, at screening
• Body mass index (BMI) : 18.0-30.0 kg/m2, inclusive, at screening
• Status : healthy subjects
• At screening, females must be non-pregnant and non-lactating, or of non-childbearing potential (either surgically sterilized or physiologically incapable of becoming pregnant, or at least 1 year post-menopausal \[amenorrhoea duration of 12 consecutive months\]); non-pregnancy will be confirmed for all females by a serum pregnancy test conducted at screening, and a urine pregnancy test at each admission and at follow-up
• Female subjects of childbearing potential, with a fertile male sexual partner, must agree to use adequate contraception from screening until 90 days after the follow-up visit. Adequate contraception is defined as using a non-hormonal intrauterine device combined with at least 1 of the following forms of contraception: a diaphragm or cervical cap, or a condom; please note that hormonal contraceptives are not allowed. Also, total abstinence, in accordance with the lifestyle of the subject, is acceptable
• Male subjects, if not surgically sterilized, must agree to use adequate contraception and not donate sperm from admission to the clinical research center until 90 days after the follow-up visit. Adequate contraception for the male subject (and his female partner) is defined as using hormonal contraceptives or an intrauterine device, combined with at least 1 of the following forms of contraception: a diaphragm or cervical cap, or a condom. Also, total abstinence, in accordance with the lifestyle of the subject is acceptable
• All prescribed medication, including hormonal contraceptives for female subjects, must have been stopped at least 30 days prior to admission to the clinical research center
• All over-the-counter medication, vitamin preparations and other food supplements, or herbal medications (eg, St. John's Wort) must have been stopped at least 14 days prior to admission to the clinical research center. An exception is made for paracetamol, which is allowed up to admission to the clinical research center
• Ability and willingness to abstain from alcohol, methylxanthine-containing beverages or food (coffee, tea, cola, chocolate, energy drinks) and grapefruit (juice) from 72 hours prior to admission to the clinical research center
• Good physical and mental health on the basis of medical history, physical examination, clinical laboratory, electrocardiogram (ECG) and vital signs, as judged by the PI
• Willing and able to sign the ICF

You may not qualify if:

• Employee of PRA or the Sponsor
• History of relevant drug and/or food allergies
• Using tobacco products within 60 days prior to the first drug administration
• History of alcohol abuse or drug addiction (including soft drugs like cannabis products)
• Positive drug and alcohol screen (opiates, methadone, cocaine, amphetamines \[including ecstasy\], cannabinoids, barbiturates, benzodiazepines, tricyclic antidepressants and alcohol) at screening and admission to the clinical research center
• Average intake of more than 24 units of alcohol per week (1 unit of alcohol equals approximately 250 mL of beer, 100 mL of wine or 35 mL of spirits)
• Positive screen for hepatitis B surface antigen (HBsAg), anti-HCV antibodies or anti-human immunodeficiency virus (HIV) 1 and 2 antibodies
• Participation in a drug study within 60 days prior to the first drug administration in the current study. Participation in more than 4 other drug studies in the 12 months prior to the first drug administration in the current study
• Donation or loss of more than 100 mL of blood within 60 days prior to the first drug administration. Donation or loss of more than 1.5 liters of blood (for male subjects) / more than 1.0 liters of blood (for female subjects) in the 10 months prior to the first drug administration in the current study
• Significant and/or acute illness within 5 days prior to the first drug administration that may impact safety assessments, in the opinion of the PI

Sponsors & Collaborators

• F-star Therapeutics, Inc.: lead
• PRA Health Sciences: collaborator

Study Sites (1)

University Medical Center Groningen

Groningen, Netherlands

Location

MeSH Terms

Interventions

Midazolam

Intervention Hierarchy (Ancestors)

Benzodiazepines; Benzazepines; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Heterocyclic Compounds

Results Point of Contact

• Title: Don Mitchell, Vice President, Operations & Corporate Development
• Organization: Spring Bank Pharmaceuticals, Inc.

dmitchell@springbankpharm.com

(508) 689-9737

Study Officials

• Jeroen van de Wetering

  PRA Health Sciences

  PRINCIPAL INVESTIGATOR

Publication Agreements

• PI is Sponsor Employee: Yes

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SEQUENTIAL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 3, 2018
• First Posted: April 10, 2018
• Study Start: May 7, 2018
• Primary Completion: August 27, 2018
• Study Completion: August 27, 2018
• Last Updated: October 8, 2020
• Results First Posted: October 8, 2020

Record last verified: 2020-09

Locations

NL (1)